menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Making a Difference: Patient-Centered Ulcerative Colitis Care in the Era of JAK Inhibitors and S1P Modulators

3 chapters
Play All
0.75 credits
45 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.75 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    The goal of this program is to improve the overall management of patients with ulcerative colitis (UC). Specifically, we aim to improve clinician knowledge and competence with respect to the novel mechanisms of action of sphingosine-1-phosphate receptor (S1P) modulators and Janus kinase (JAK) inhibitors and their respective roles in the overall treatment paradigm of UC.  We also aim to improve patient-centered approaches to the management of UC with a particular focus on underserved communities and Black, Indigenous, and people of color (BIPOC). To bolster our commitment to these patient populations, Boston University Chobanian & Avedisian School of Medicine  partnered with Color of Crohn’s & Chronic Illness (COCCI) for this initiative.

    Endorsed by the AGA Institute

  • Disclosure of Conflicts of Interest

    Disclosure Policy

    Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 

    In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.

    Speaker Disclosures

    Dr. Sophia Balzora is a consultant for Bristol Myers Squibb, Janssen, Pfizer and Takeda.
    Dr. Alan Moss and Ms. Latonia Ward have no relevant financial relationships to disclose.

    The speakers do not plan on discussing unlabeled/investigational uses of a commercial product.

    Planning Team Disclosures

    The following members of Boston University Chobanian & Avedisian School of Medicine, Center for Continuing Education have no relevant financial relationships to disclose:

    Michael Burk, BS, Senior Program Manager, BU CCE
    Chris Drury, MA, MA medical writer of Quill Consulting
    Susan Dybowski, RN, Nursing Advisor of Boston Children’s Hospital
    Sharmeel Wasan, MD, CME Physician Advisory, of Boston University School of Medicine and Boston Medical Center.

  • Target Audience

    This activity is designed for gastroenterology providers including physicians, physician assistants, nurse practitioners and nurses.

  • Learning Objectives

    At the conclusion of the activity, participants will be better able to:

    1. Explain the mechanism of action of S1P and JAK modulation as it pertains to the treatment of ulcerative colitis.
    2. Describe the practical implementation of S1P receptor modulators and JAK inhibition in the treatment of ulcerative colitis.
    3. Utilizing a shared decision-making approach, develop patient-centered treatment management plans that reflect individualized patient goals.
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    CME Designation Statement

    Boston University Chobanian & Avedisian School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ANCC Designation Statement

    Nursing Contact Hours: 0.75, of which .50 are eligible for pharmacology credit

  • Disclaimer

    THIS CONTINUING EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.

  • Provider(s)/Educational Partner(s)

    This activity has been planned and provided by Boston University Chobanian & Avedisian School of Medicine.

  • Commercial Support

    This activity is supported by an educational grant from Bristol Myers Squibb Company.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    The goal of this program is to improve the overall management of patients with ulcerative colitis (UC). Specifically, we aim to improve clinician knowledge and competence with respect to the novel mechanisms of action of sphingosine-1-phosphate receptor (S1P) modulators and Janus kinase (JAK) inhibitors and their respective roles in the overall treatment paradigm of UC.  We also aim to improve patient-centered approaches to the management of UC with a particular focus on underserved communities and Black, Indigenous, and people of color (BIPOC). To bolster our commitment to these patient populations, Boston University Chobanian & Avedisian School of Medicine  partnered with Color of Crohn’s & Chronic Illness (COCCI) for this initiative.

    Endorsed by the AGA Institute

  • Disclosure of Conflicts of Interest

    Disclosure Policy

    Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 

    In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.

    Speaker Disclosures

    Dr. Sophia Balzora is a consultant for Bristol Myers Squibb, Janssen, Pfizer and Takeda.
    Dr. Alan Moss and Ms. Latonia Ward have no relevant financial relationships to disclose.

    The speakers do not plan on discussing unlabeled/investigational uses of a commercial product.

    Planning Team Disclosures

    The following members of Boston University Chobanian & Avedisian School of Medicine, Center for Continuing Education have no relevant financial relationships to disclose:

    Michael Burk, BS, Senior Program Manager, BU CCE
    Chris Drury, MA, MA medical writer of Quill Consulting
    Susan Dybowski, RN, Nursing Advisor of Boston Children’s Hospital
    Sharmeel Wasan, MD, CME Physician Advisory, of Boston University School of Medicine and Boston Medical Center.

  • Target Audience

    This activity is designed for gastroenterology providers including physicians, physician assistants, nurse practitioners and nurses.

  • Learning Objectives

    At the conclusion of the activity, participants will be better able to:

    1. Explain the mechanism of action of S1P and JAK modulation as it pertains to the treatment of ulcerative colitis.
    2. Describe the practical implementation of S1P receptor modulators and JAK inhibition in the treatment of ulcerative colitis.
    3. Utilizing a shared decision-making approach, develop patient-centered treatment management plans that reflect individualized patient goals.
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    CME Designation Statement

    Boston University Chobanian & Avedisian School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ANCC Designation Statement

    Nursing Contact Hours: 0.75, of which .50 are eligible for pharmacology credit

  • Disclaimer

    THIS CONTINUING EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.

  • Provider(s)/Educational Partner(s)

    This activity has been planned and provided by Boston University Chobanian & Avedisian School of Medicine.

  • Commercial Support

    This activity is supported by an educational grant from Bristol Myers Squibb Company.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule25 Jun 2024